Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul-Aug;60(4):381-4.
doi: 10.4103/0019-5154.160490.

Omalizumab-A Review

Kiran Godse  1 , Aayushi Mehta  1 , Sharmila Patil  1 , Manjyot Gautam  1 , Nitin Nadkarni  1
Affiliations

Omalizumab-A Review

Kiran Godse et al. Indian J Dermatol. 2015 Jul-Aug.

Abstract

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.

Keywords: Anaphylaxis; FDA approval; atopic dermatitis; chronic urticaria; monoclonal antibody.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

References

    1. Belliveau PP. Omalizumab: A monoclonal anti-IgE antibody. MedGenMed. 2005;7:27. - PMC - PubMed
    1. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569–73. - PubMed
    1. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35. - PubMed
    1. Uysal P, Eller E, Mortz CG, Bindsley-Jensen C. An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized. J Allergy Clin Immunol. 2014;133:914–5. - PubMed
    1. Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012;4:357–61. - PMC - PubMed

LinkOut - more resources